Xu Guanqun, Liang Qian, Zhang Liwei, Shen Yun, Ding Qiulan, Wang Xuefeng, Wang Hongli
Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.
Zhonghua Xue Ye Xue Za Zhi. 2015 Oct;36(10):844-8. doi: 10.3760/cma.j.issn.0253-2727.2015.10.008.
To perform phenotypic diagnosis, genetic diagnosis and prenatal diagnosis of inherited coagulation factor XIII (FXIII)deficiency in a Chinese family also provide a review of inherited coagulation F XIII deficiency.
The activity levels of F XIII (F XIII:C) of proband and family members were measured by clot solubility test and REA-chrom F XIII kit. The antigen levels of F XIII(FXIII:Ag) were measured by enzyme-linked immunosorbent assay. Thrombelastography (TEG) test was used to make a comprehensive evaluation of coagulation status in the proband. All 15 exons and exon-intron boundaries of the F13A1 gene were amplified by PCR, and DNA sequencing was performed then. The mutation identified in the proband was screened in the family members. Furthermore, the related literatures were reviewed to provide a profile of clinical manifestation, gene mutations, the relationship between the mutations and phenotype, and treatments of inherited coagulation F XIII deficient cases.
The clot solubility test was positive in the proband. The FXIII:Ag level of the proband was less than 1% and the FXIII:C level was below the lower limit of detection (<3%). Two compound heterozygous missense mutations (p.Arg662* and p.Trp665*) were identified in the proband. Family study showed that the two mutations were both inherited from the parents. The fetus also carried two compound heterozygous mutations, the same as the proband, and was diagnosed with severe F XIII deficiency. As reported in the literatures, most mutations were missense mutations and nonsense mutations, and no hot spot was found. The clinical pattern of F XIII deficiency varied among patients, with potentially fatal consequences from severe bleeding complications.
Better understanding of F XIII biochemical properties and function and developing of FXIII laboratory assays and genetic detection could prevent missed diagnosis, and patients moght benefit from better care.
对一个中国家系的遗传性凝血因子 XIII(FXIII)缺乏症进行表型诊断、基因诊断和产前诊断,并对遗传性凝血因子 XIII 缺乏症进行综述。
采用凝块溶解度试验和 REA-chrom F XIII 试剂盒检测先证者及家庭成员的 FXIII(FXIII:C)活性水平。采用酶联免疫吸附试验检测 FXIII(FXIII:Ag)抗原水平。采用血栓弹力图(TEG)试验对先证者的凝血状态进行综合评估。通过聚合酶链反应(PCR)扩增 F13A1 基因的全部 15 个外显子和外显子-内含子边界,然后进行 DNA 测序。在先证者中鉴定出的突变在家庭成员中进行筛查。此外,对相关文献进行综述,以提供遗传性凝血因子 XIII 缺乏症病例的临床表现、基因突变、突变与表型的关系及治疗情况。
先证者的凝块溶解度试验呈阳性。先证者的 FXIII:Ag 水平低于 1%,FXIII:C 水平低于检测下限(<3%)。在先证者中鉴定出两个复合杂合错义突变(p.Arg662和 p.Trp665)。家系研究表明,这两个突变均遗传自父母。胎儿也携带与先证者相同的两个复合杂合突变,被诊断为严重 FXIII 缺乏症。如文献报道,大多数突变是错义突变和无义突变,未发现热点突变。FXIII 缺乏症的临床模式在患者中各不相同,严重出血并发症可能导致致命后果。
更好地了解 FXIII 的生化特性和功能,开发 FXIII 实验室检测方法和基因检测方法可以防止漏诊,患者可能会从更好的治疗中受益。